Strategies for pharmacologic modulation of the heart failure phenotype.

Abstract excerpt

The end-stage heart failure phenotype is characterized by marked dyspnea on exertion, edema, and overwhelming fatigue, and by a high incidence of sudden death. Patients who display the end-stage phenotype have transitioned from a normal phenotype with myocardial damage at a cellular level. This transition appears to be mediated by events at both the cellular and molecular levels. Until recently, it was generally...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adrenergic beta-Antagonists
• Share to Angiotensin-Converting Enzyme Inhibitors